Trials / Completed
CompletedNCT01970098
A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 374 (actual)
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety and pharmacokinetics of KPS-0373 in SCD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KPS-0373, High dose | 28 weeks |
| DRUG | KPS-0373, Low dose | 28 weeks |
| DRUG | Placebo | 28 weeks |
Timeline
- Start date
- 2013-10-09
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2013-10-25
- Last updated
- 2018-12-14
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01970098. Inclusion in this directory is not an endorsement.